PLD1 and glioblastoma: In detail, PLD1 inhibition sensitizes GSCs to the alkylating agent and reduces glioblastoma tumorigenesis, pointing out the aim of the current research on glioblastoma, which is focused on any novel therapy that could address GSC-driven tumor recurrence and resistance to TMZ.